JP2018508593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508593A5 JP2018508593A5 JP2018500281A JP2018500281A JP2018508593A5 JP 2018508593 A5 JP2018508593 A5 JP 2018508593A5 JP 2018500281 A JP2018500281 A JP 2018500281A JP 2018500281 A JP2018500281 A JP 2018500281A JP 2018508593 A5 JP2018508593 A5 JP 2018508593A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administered
- combination
- entinostat
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 46
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 35
- 229950005837 entinostat Drugs 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 16
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 15
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 13
- 201000001441 melanoma Diseases 0.000 claims description 12
- 238000002648 combination therapy Methods 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 230000002250 progressing effect Effects 0.000 claims description 4
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021130582A JP7540980B2 (ja) | 2015-03-20 | 2021-08-10 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
| JP2024072421A JP2024091945A (ja) | 2015-03-20 | 2024-04-26 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136303P | 2015-03-20 | 2015-03-20 | |
| US62/136,303 | 2015-03-20 | ||
| US201562137601P | 2015-03-24 | 2015-03-24 | |
| US62/137,601 | 2015-03-24 | ||
| PCT/US2016/023298 WO2016154068A1 (en) | 2015-03-20 | 2016-03-18 | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130582A Division JP7540980B2 (ja) | 2015-03-20 | 2021-08-10 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018508593A JP2018508593A (ja) | 2018-03-29 |
| JP2018508593A5 true JP2018508593A5 (https=) | 2019-03-07 |
Family
ID=56977796
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500281A Pending JP2018508593A (ja) | 2015-03-20 | 2016-03-18 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ |
| JP2021130582A Active JP7540980B2 (ja) | 2015-03-20 | 2021-08-10 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
| JP2024072421A Pending JP2024091945A (ja) | 2015-03-20 | 2024-04-26 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130582A Active JP7540980B2 (ja) | 2015-03-20 | 2021-08-10 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
| JP2024072421A Pending JP2024091945A (ja) | 2015-03-20 | 2024-04-26 | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11324822B2 (https=) |
| EP (1) | EP3270966B1 (https=) |
| JP (3) | JP2018508593A (https=) |
| KR (1) | KR20170124604A (https=) |
| CN (1) | CN107614011A (https=) |
| AU (2) | AU2016235434B2 (https=) |
| BR (1) | BR112017020002A2 (https=) |
| ES (1) | ES2986548T3 (https=) |
| IL (3) | IL254529B2 (https=) |
| MX (1) | MX2017012113A (https=) |
| WO (1) | WO2016154068A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2016318136B2 (en) | 2015-09-02 | 2022-10-20 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| US20190183870A1 (en) * | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| RU2018130831A (ru) | 2016-01-28 | 2020-03-02 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11497746B2 (en) | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
| WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| KR20200051712A (ko) * | 2017-09-08 | 2020-05-13 | 4에스체 악티엔게젤샤프트 | 암 치료를 위한 면역 체크포인트 조절제와 조합된 hdac 억제제 |
| US20210024633A1 (en) * | 2018-03-28 | 2021-01-28 | Ensemble Group Holdings | Methods of treating cancer in subjects having dysregulated lymphatic systems |
| AU2019266231B2 (en) * | 2018-05-07 | 2025-08-21 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| AU2019285640A1 (en) | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| WO2019240872A1 (en) * | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| WO2021129616A1 (zh) * | 2019-12-23 | 2021-07-01 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 |
| WO2024222705A1 (zh) * | 2023-04-25 | 2024-10-31 | 深圳微芯生物科技股份有限公司 | 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途 |
| US20240382463A1 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same |
| US12553903B2 (en) | 2023-06-01 | 2026-02-17 | Cg Pharmaceuticals, Inc | Ivaltinostat combination therapy for treating pancreatic cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US20130150386A1 (en) | 2011-12-09 | 2013-06-13 | Syndax Pharmaceuticals, Inc. | Methods for the treatment of lung cancer |
| US8987067B2 (en) * | 2013-03-01 | 2015-03-24 | International Business Machines Corporation | Segmented guard ring structures with electrically insulated gap structures and design structures thereof |
| CA2917858A1 (en) * | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| WO2015035112A1 (en) * | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| US10869926B2 (en) * | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| US20180353602A1 (en) * | 2015-06-29 | 2018-12-13 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer |
| AU2016318136B2 (en) * | 2015-09-02 | 2022-10-20 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
-
2016
- 2016-03-18 JP JP2018500281A patent/JP2018508593A/ja active Pending
- 2016-03-18 IL IL254529A patent/IL254529B2/en unknown
- 2016-03-18 CN CN201680028952.1A patent/CN107614011A/zh active Pending
- 2016-03-18 MX MX2017012113A patent/MX2017012113A/es unknown
- 2016-03-18 EP EP16769460.3A patent/EP3270966B1/en not_active Revoked
- 2016-03-18 IL IL323063A patent/IL323063A/en unknown
- 2016-03-18 IL IL307850A patent/IL307850A/en unknown
- 2016-03-18 BR BR112017020002-3A patent/BR112017020002A2/en not_active Application Discontinuation
- 2016-03-18 US US15/559,402 patent/US11324822B2/en active Active
- 2016-03-18 WO PCT/US2016/023298 patent/WO2016154068A1/en not_active Ceased
- 2016-03-18 ES ES16769460T patent/ES2986548T3/es active Active
- 2016-03-18 KR KR1020177030064A patent/KR20170124604A/ko not_active Ceased
- 2016-03-18 AU AU2016235434A patent/AU2016235434B2/en active Active
-
2021
- 2021-08-10 JP JP2021130582A patent/JP7540980B2/ja active Active
-
2022
- 2022-04-08 US US17/716,547 patent/US20230022573A1/en not_active Abandoned
- 2022-05-03 AU AU2022202954A patent/AU2022202954A1/en not_active Abandoned
-
2024
- 2024-04-26 JP JP2024072421A patent/JP2024091945A/ja active Pending
- 2024-08-08 US US18/797,933 patent/US20240398944A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508593A5 (https=) | ||
| JP2017537070A5 (https=) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| JP2015532292A5 (https=) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| JP2014528423A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| MX2018005071A (es) | Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. | |
| JP2016520082A5 (https=) | ||
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| JP2018522045A5 (https=) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2753523C2 (ru) | УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ | |
| JP2019532047A5 (https=) | ||
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors |